LLY raised 2026 guidance to $82B-$85B as Mounjaro and Zepbound surged, while NVO guided to an adjusted sales decline and cut 9,000 jobs. <\/p>\n<\/li>\n
Novo pre-announced 50% Wegovy and 35% Ozempic price cuts effective January 2027, capping future cash flow but protecting volume as NVO trades at a P\/E near 12. <\/p>\n<\/li>\n
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Eli Lilly didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/li>\n<\/ul>\n Novo Nordisk<\/strong> (NYSE: NVO<\/a>) and Eli Lilly<\/strong> (NYSE: LLY<\/a>) both posted Q1 FY2026 results this spring, and the gap between them keeps widening. <\/p>\n Lilly delivered 55.55% revenue growth and raised guidance. Novo, meanwhile, is quietly restructuring after guiding to an adjusted sales decline of -4% to -12% at constant currency. Same drug class, very different quarters. <\/p>\n Foundayo Sprints. Wegovy Pill Defends. <\/p>\n Lilly’s Q1 was a blowout. Mounjaro rang up $8.66 billion (+125% YoY), and Zepbound added $4.16 billion (+80%). Volume climbed 65%, more than absorbing a 13% price drop. The centerpiece was Foundayo (orforglipron), the first approved GLP-1 pill with no food or water restrictions. That is a real manufacturing edge over injectable peptides. <\/p>\n Novo’s headline looked massive, $96.82 billion in revenue, but that number carried a $4.20 billion non-cash reversal of a US 340B provision. Strip that out and adjusted sales slipped 4% at constant exchange rates. <\/p>\n Ozempic fell to $27.83 billion (-8%). The bright spot: the Wegovy pill hit $2.26 billion in its first full quarter and reached over 1 million patients since its January launch. CEO Mike Doustdar called it “the most efficacious GLP-1 tablet” on the market. Impressive, but not enough to offset Ozempic and Rybelsus fatigue. <\/p>\n Act now:<\/strong> the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Eli Lilly didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n Expansion Mode vs. Damage Control <\/p>\n Lens<\/strong> <\/p>\n<\/td>\n Eli Lilly<\/strong> <\/p>\n<\/td>\n Novo Nordisk<\/strong> <\/p>\n<\/td>\n<\/tr>\n Core Bet <\/p>\n<\/td>\n Tirzepatide plus oral orforglipron <\/p>\n<\/td>\n Semaglutide franchise defense <\/p>\n<\/td>\n<\/tr>\n 2026 Guidance <\/p>\n<\/td>\n Raised to $82B-$85B <\/p>\n<\/td>\n -4% to -12% CER <\/p>\n<\/td>\n<\/tr>\n Pipeline Depth <\/p>\n<\/td>\n Retatrutide, Kisunla, Ebglyss, Jaypirca <\/p>\n<\/td>\n Wegovy HD, Zenagamtide (CagriSema shelved) <\/p>\n<\/td>\n<\/tr>\n Leadership Tone <\/p>\n<\/td>\n Offense <\/p>\n<\/td>\n Restructuring <\/p>\n<\/td>\n<\/tr>\n Ricks used Q1 to announce four acquisitions (Orna, Centessa, Kelonia, Ajax). Doustdar, by contrast, is presiding over a company that already cut roughly 9,000 positions and pre-announced list price cuts of roughly 50% for Wegovy and 35% for Ozempic effective January 1, 2027. <\/p>\n That protects volume. It also caps 2027 cash flow. And CagriSema, once the marquee follow-on, missed its REDEFINE 4 primary endpoint and was terminated as a co-formulation. <\/p>\n The Next Test Is Lilly’s Q2 Earnings Report <\/p>\n Lilly reports Q2 on August 5. Prediction markets currently put a 70% probability on another earnings beat, with 96.4% odds Mounjaro clears $7.5 billion and 87% odds Zepbound tops $4 billion. I want to see whether Foundayo scripts scale fast enough to justify Lilly’s 53.02% one-year gain. <\/p>\n For Novo, keep an eye on the stock as Wegovy pill launches outside the US in H2 2026 and the Medicare Part D obesity pilot begins July 1, 2026. <\/p>\n Why Lilly Leads, While Novo Stays in the Mix <\/p>\n On momentum, Lilly is still the cleaner story. Volume is growing 65%, guidance keeps moving up, and Foundayo directly beat oral semaglutide in a head-to-head Phase 3 trial. The company setting the pricing floor arguably has a stronger position than the one reacting to it. <\/p>\n That said, Novo trades at a P\/E near 12 with a 12.78% post-earnings recovery and a 3% dividend. For a turnaround investor patient enough to wait through the 2027 price reset, that setup is defensible. Avoiding both would only make sense if one doubted GLP-1 demand itself, which the numbers make hard to argue. <\/p>\n Act now:<\/strong> the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Eli Lilly didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/a> Eli Lilly and Co. <\/p>\n
<\/a> LLY Earnings Explorer \u2014 24\/7 Wall St. <\/p>\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n